Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 26:50:61.
doi: 10.11604/pamj.2025.50.61.46684. eCollection 2025.

Moderate-to-severe hypercalcemia secondary to primary hyperparathyroidism refractory to conventional treatment (therapeutic management with denosumab): case report and literature review

Manuel Carpio Salmerón  1 , Mariano Tébar Caballero  2 , Luis Marin Martinez  1 , Cristian Marco-Alacid  3
Affiliations
Review

Moderate-to-severe hypercalcemia secondary to primary hyperparathyroidism refractory to conventional treatment (therapeutic management with denosumab): case report and literature review

Manuel Carpio Salmerón et al. Pan Afr Med J. .

Abstract

Severe hypercalcemia resistant to conventional medical treatment is a rare complication of primary hyperparathyroidism, and published information on the use of denosumab in patients with this condition is limited. This article aims to review the current literature on the utility of denosumab as a hypocalcemic agent in the context of a real clinical case. We present the case of an 87-year-old woman with nonspecific symptoms of constipation and asthenia who was diagnosed with severe hypercalcemia secondary to primary hyperparathyroidism. Treatment with cinacalcet, bisphosphonates, and hydration was ineffective, so denosumab was used until surgery. Denosumab stabilized calcium levels, improved renal function, and alleviated the patient's symptoms. Our study highlights that denosumab is a useful tool in managing hypercalcemia associated with primary hyperparathyroidism, either as a preoperative measure or when surgery is contraindicated.

Keywords: Denosumab; case report; hypercalcemia; parathyroid hormone; primary hyperparathyroidism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Figure 1
Figure 1
temporal evolution of serum calcium + interventions
Figure 2
Figure 2
temporal evolution of parathyroid hormone (mg/dl)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Partida M, Allo Miguel G, Martínez Díaz-Guerra G. Hiperparatiroidismo primario sintomático, asintomático y normocalcémico. Sociedad Española de Endocrinología y Nutrición. 2024.
    1. Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022 Oct 25;328(16):1624–1636. - PubMed
    1. Walker MD, Silverberg SJ. Primary Hyperparathyroidism. Nat Rev Endocrinol. 2018 Feb;14(2):115–125. - PMC - PubMed
    1. Fuleihan GEH, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 Feb 15;108(3):507–528. - PubMed
    1. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022 Nov;37(11):2293–2314. - PubMed

MeSH terms

LinkOut - more resources